Last reviewed · How we verify
NCT05500118
Establishment of a Decision Aid Tool for Asymptomatic Small Leiomyoma and Analysis of Influencing Factors for Clinical Decision-making Using HIFU
trial testing Patients Decision Aids in Leiomyoma, Uterine in 120 participants. Currently enrolling.
31 August 2024
Quick facts
| Lead sponsor | Shenzhen Maternity & Child Healthcare Hospital |
|---|---|
| Status | Recruiting now |
| Study type | OBSERVATIONAL |
| Enrollment | 120 |
| Start date | 31 August 2022 |
| Primary completion | 31 August 2024 |
| Estimated completion | 31 August 2027 |
| Sites | 1 location across China |
Drugs / interventions tested
- Patients Decision Aids
Conditions studied
- Leiomyoma, Uterine — all drugs for Leiomyoma, Uterine →
- High-Intensity Focused Ultrasound Ablation — all drugs for High-Intensity Focused Ultrasound Ablation →
- Patients Decision Aids — all drugs for Patients Decision Aids →
Sponsor
Shenzhen Maternity & Child Healthcare Hospital
Who can join
Adults 18 to 55, female only, with Leiomyoma, Uterine or High-Intensity Focused Ultrasound Ablation. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
With the younger patients diagnosed with asymptomatic leiomyoma, delay in the reproductive age of women, the advancement of medical technology, and the rapid development of treatment methods, there are many choices between gynecologists, gynecologists and patients because of experience and knowledge. It is not easy to make the most favorable choice for patients. This study is mainly led by a committee composed of designers, doctors, nurses and patients, and based on clinical guidelines and evidence-based medicine. Co-operating with patients with asymptomatic small leiomyoma, we want to find the influencing factors of clinical decision-making, and to establish a patient decision aid tool. We use prospective trial to verify that the use of this tool can improve patients' decision-making efficacy and further improve patient-reported outcomes.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT05500118
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Leiomyoma, Uterine
Currently open trials in the same condition.
- NCT06143631 — Prescription of Letrozole for Uterine Myoma · Phase 4 · recruiting
- NCT05364008 — FRIEND: Fibroids and Unexplained Infertility Treatment With Epigallocatechin Gallate; A Natural CompounD in Green Tea · Phase 3 · active not recruiting
- NCT05607602 — Are Uterine Fibroids Pro-thrombotic? · active not recruiting
- NCT03400826 — Effects of Simvastatin on Uterine Leiomyoma Size · Phase 2 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05500118 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Shenzhen Maternity & Child Healthcare Hospital
- Last refreshed: 12 August 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05500118.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing